

AMENDMENTS TO THE SPECIFICATION

Please revise the specification as follow. Deletions are indicated by ~~strikethrough~~ and insertions are indicated by underlining.

Please amend page 24, lines 26-30 as follows:

The present invention encompasses the use of MEDI-507 ("siplizumab", MedImmune, Inc., Gaithersburg, MD; Branco *et al.*, 1999, *Transplantation* 68(10):1588-1596), an analog derivative or an antigen-binding fragment thereof (*e.g.*, one or more complementarity determining regions ("CDRs") of MEDI-507) in the prevention, treatment, management or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof.